Pharmaceuticals, Biotechnology and Life Sciences
LAVAL, Québec–(BUSINESS WIRE)–#Altasciences–Insert in first paragraph, first sentence of release issued May 22, 2019, at 8:04 a.m. ET: New text.…
ROSEMONT, Ill.–(BUSINESS WIRE)–#Proteintech–Proteintech, the benchmark in antibodies and proteins, welcomes Frank Schestag, PhD, as Commercial Director. He will be providing…
MILAN & MONTREAL–(BUSINESS WIRE)–$NWRN–Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of novel…
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
Biomarck Pharmaceuticals has improved the Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase 2 study in NSCLC, which compares standard of care alone, to SOC plus BIO-11006 in 60 patients with stage 4.
Earnings call slated for July 29, 6:30 PM IST / 9:00 AM EDT HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE:…
800 Leaders Unite to Advance Rapid Diagnostics Opening New Frontiers in Precision Medicine WASHINGTON–(BUSINESS WIRE)–#Biomarkers–Responding to the growth of the…
Trovagene has started erolling patients for its second phase study of onvansertib plus FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.
BioNTech pulled one of the largest private EU biotech funding events expands global shareholder base with $325 from investors
– Selected by the FTSE4Good Developed Index for the 15th consecutive year – Named to the MSCI ESG Leaders Index…